ClinicalTrials.gg
CompletedNCT06655311Updated Oct 23, 2024

A Study of Enlicitide Chloride (MK-0616) in Healthy Participants and Participants Taking Statins (MK-0616-012)

A Phase 1 interventional study of Enlicitide Chloride and Placebo in Healthy and Hypercholesterolemia, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-23.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jan 2024, 2 years 10 months ago, and no results have been posted to the registry.
  • Registered 2 years after the study started (first participant enrolled Sep 2022, registered Oct 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies in Hypercholesterolemia by Merck & Co., Inc — 1 open to participants now, 3 under way, 3 of them phase 3. Hypercholesterolemia · Merck & Co., Inc.

Enrollment
22nd of 27
56 · median 500
Started
2022
with 2 others
Phase 1
6 of 29
none open now
Registered
28th of 29
by date

Among the 29 studies in Hypercholesterolemia by Merck & Co., Inc, this one is the 22nd largest by enrollment of the 27 interventional ones that give a count, is one of 3 that started in 2022, is one of 6 in phase 1, and was the 28th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 29 studies in Hypercholesterolemia by Merck & Co., Inc is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Hypercholesterolemia by Merck & Co., Inc, or all of them as a file.
02

Study summary

The goal of this study is to learn what happens to different doses of enlicitide chloride over time in the body of healthy participants and participants taking statins, a group of medicines used to reduce the levels of high cholesterol in the bloodstream. The researchers want to learn about the safety of enlicitide chloride when administered at high doses.

03

Conditions studied

  • Healthy
  • Hypercholesterolemia
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The key inclusion criteria include but are not limited to the following:

  • Is in good health based on medical history, physical examination, vital signs (VS) measurements, (ECGs), and laboratory safety tests performed before randomization
  • Has a (BMI)≥18 and ≤32 kg/m\^2

Exclusion criteria

Exclusion Criteria:

The key exclusion criteria include but are not limited to the following:

  • Has a history of endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major (including stroke and chronic seizures) abnormalities or diseases
  • Has a history of cancer
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    Enlicitide Chloride

    Participants receive enlicitide chloride titrated orally from Dose 1, Dose 2, or Dose 3 once daily (QD) over the course of a 14-day treatment for each dose based on the safety and tolerability of the previous starting dose. The total treatment duration is up to approximately 6 weeks.

    Biological: Enlicitide Chloride

  • Placebo comparator
    Placebo

    Participants receive placebo orally for up to approximately 6 weeks.

    Other: Placebo

Interventions

  • Oral administration

    Also known as: MK-0616

  • OtherPlacebo

    Oral administration

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experience an Adverse Event (AE)

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be reported.

    Time frame: Up to approximately 56 days

  2. Number of Participants Who Discontinue Study Treatment Due to an AE

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study treatment due to an AE will be reported.

    Time frame: Up to approximately 42 days

Secondary outcomes

  1. Area Under the Curve from Time 0 to 24 Hours (AUC0-24) of Enlicitide Chloride

    Blood samples will be collected to determine the AUC0-24 of enlicitide chloride.

    Time frame: At designated timepoints (up to approximately 24 hours)

  2. Maximum Plasma Concentration (Cmax) of Enlicitide Chloride

    Blood samples will be collected to determine the Cmax of enlicitide chloride.

    Time frame: At designated timepoints (up to approximately 1 week)

  3. Plasma Concentration 24 Hours Postdose (C24) of Enlicitide Chloride

    Blood samples will be collected to determine the C24 of enlicitide chloride.

    Time frame: At designated timepoints (up to approximately 1 week)

  4. Time to Maximum Plasma Concentration (Tmax) of Enlicitide Chloride

    Blood samples will be collected to determine the Tmax of enlicitide chloride.

    Time frame: At designated timepoints (up to approximately 1 week)

  5. Area Under the Concentration-Time Curve from Time 0 to Last (AUC0-Last) of Enlicitide Chloride

    Blood samples will be collected to determine the AUC0-Last of enlicitide chloride.

    Time frame: At designated timepoints (up to approximately 1 week)

  6. Percent Change from Baseline of Plasma Low Density Lipoprotein (LDL-C) Concentration After Administration of Enlicitide Chloride

    Blood samples will be collected to determine the LDL-C of enlicitide chloride.

    Time frame: Baseline, Week 1

07

Study locations

1 site
  • Altasciences Clinical Kansas, Inc. (Site 0002)
    Overland Park, Kansas 66212, United States
08

References and documents

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2022 to primary completion in Jan 2024, 15 months.

Of 41 industry-sponsored phase 1 interventional studies under Hypercholesterolemia, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 15 months is above that.

Counting every sponsor, half of 46 studies reached it within 7 months; a quarter within 2 and three quarters within 10.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2024
First posted
Oct 23, 2024
StartActual
Sep 30, 2022
Primary completionActual
Jan 2, 2024
CompletionActual
Jan 2, 2024
Last update
Oct 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06655311
Responsible party
Sponsor
First posted
Oct 23, 2024
Start date
Sep 30, 2022
Primary completion
Jan 2, 2024
Completion
Jan 2, 2024
Last update
Oct 23, 2024

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enlicitide chloride

Start the discussion